Garon EB, Hellmann MD, Costa EC, et al. Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001. ASCO Annual Meeting 2019, abstract LBA9015.
177Lu-Dotataat plus octreotide bij neuro-endocriene tumoren: NETTER-2
sep 2024 | Maag-darm-leveroncologie